Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer

ABSTRACT: This exploratory, open label study will assess the the dose-effect relationship, efficacy and safety of RO5323441 in patients with metastatic treatment-refractory colorectal or ovarian cancer. Cohorts of patients will receive doses of intravenous RO5323441 in the range of 25mg to 3g every 1 or 2 weeks and will undergo serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessments. In the absence of disease progression and unacceptable toxicity, patients may continue to receive their maximum dose of RO5323441 for a core treatment phase of up to a total of 6 months. Treatment with RO5323441 can be extended at the investigator’s discretion until disease progression or unacceptable toxicity occurs. Target sample size is <100.

DISEASE(S): Carcinoma, Ovarian Epithelial,Ovarian Neoplasms,Colorectal Cancer, Ovarian Cancer

PROVIDER: 2091042 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia

Project description:Acute myeloid leukemia (AML) is an aggressive malignancy that can only be cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related morbidity and mortality. Disease-stabilizing therapy is then the only possible strategy, one alternative being treatment based on all-trans retinoic acid (ATRA) combined with the histone deacetylase inhibitor valproic acid and possibly low-toxicity conventional chemotherapy.

2017-10-25 | GSE106096 | GEO

Proteomic analysis of patients with advanced triple-negative breast cancer

Project description:In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this multicentered phase II trial (NCT04303741), 46 patients with pretreated advanced TNBC were enrolled to receive camrelizumab 200 mg (day 1), and apatinib 250 mg daily, plus eribulin 1.4 mg/m2 (day 1 and 8) on a 21-day cycle until progression, or unacceptable toxicity. We performed correlation analysis between the patient's baseline protein expression level and curative effect.

2022-05-04 | PXD033655 |

RNA sequensing data of a phase 2 clinical trial of pancreatic ductal adenocarcinoma treated with entinostat in combination with nivolumab

Project description:We conducted a single-center, open-label, Simon two-stage, phase II study of entinostat in combination with the PD1 inhibitor nivolumab in patients with advanced pancreatic ductal adenocarcinoma. Patients received oral entinostat 5 mg once a week. After a 14-day lead-in with entinostat monotherapy, patients concurrently receive entinostat 5 mg orally once a week plus nivolumab 240 mg intravenously until the time of progression or unacceptable toxicities.

2024-07-29 | GSE248014 | GEO

A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.

Project description:Interventions: A: Within 56 days after surgery, patients receive infusional oxaliplatin and oral capecitabine. Patients receive infusional bevacizumab as from second course. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. B: Patients receive infusional oxaliplatin, bevacizumab and oral capecitabine. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients do not receive bevacizumab at last course. Within 56 days after chemotherapy, patients receive surgery. Primary outcome(s): Treatment compliance (phase II) Progression-free survival (phase III) Study Design: Parallel Randomized

| 2619239 | ecrin-mdr-crc

Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.

Project description:Interventions: Patients receive FOLFIRI with bevacizumab (Treatment will be continued unless the disease progression, unacceptable toxicity, or consent withdrawal.) Primary outcome(s): Efficacy: Response rate Study Design: Single arm Non-randomized

| 2617305 | ecrin-mdr-crc

Gene expression profile of FFPE samples collected with translational purposes from the MITO16/MaNGO-OV2 clinical trial

Project description:MITO16/MaNGO-OV2 (NCT01706120) is a multicenter, phase IV, single arm trial for advanced stage IIIB-IV or recurrent, previously untreated, ovarian cancer patients receiving carboplatin, paclitaxel plus bevacizumab for six 3-weekly cycles followed by bevacizumab single agent until progression or unacceptable toxicity up to a maximum of 22 total cycles. The trial that was specifically designed with a translational primary endpoint to explore if selected clinical and biological factors could identify ovarian cancer patients with better prognosis in terms of progression free survival and overall survival after combined first-line treatment with chemotherapy plus Bevacizumab. The translational study, designed together with the clinical trial, the translational study implicated the collection of patients’ tissue (formalin-fixed paraffin-embedded – FFPE) and blood samples. Gene expression profile was among the molecular analyses proposed on FFPE samples.

2023-04-19 | GSE208103 | GEO

Multicenter phase II study of modified FOLFOX6 and bevacizumab in chemonaive advanced or recurrent colorectal cancer.

Project description:Interventions: Patients receive modified FOLFOX6 with bevacizumab (Treatment will be continued to 24 cycles unless the disease progression, unacceptable toxicity, or consent withdrawal.). Primary outcome(s): Efficacy: Response rate Study Design: Single arm Non-randomized

| 2616982 | ecrin-mdr-crc

Transcription profiling of human tumours at baseline and after 21 days of treatment with sorafenib and dacarbazine

Project description:Background New approaches are needed to improve prognostic accuracy for treatment response and to explore the complexities of drug effects on human tumours. We developed a strategy of global genomic investigation of sequential tumor biopsies at baseline and 21 days post-treatment, and applied this approach in a phase I study of sorafenib plus dacarbazine in patients with solid tumours. Methods 23 patients received 21-day cycles of oral sorafenib, 400 mg twice daily and dacarbazine, 1000 mg/m2 by 1-h intravenous infusion on day 1. Efficacy was assessed using response evaluation criteria in solid tumours. Differential gene expression was assessed through genomic microarray analysis of biopsy tissue from the same tumour at baseline and on day 21. Seven parameters characterizing vascularisation using dynamic enhanced-contrast ultrasonography (DCE-US) were assessed. Changes from baseline in the two parameters were characterized for patients with and without a clinical response to treatment at 3 months.Findings 23 patients were evaluable for efficacy and 17 for gene expression and DCE-US analyses. One patient had a partial response; 14 had stable disease. Genomic analyses identified a 247-gene signature that distinguished progressors from nonprogressors at 3 months. Expression of four genes was significantly associated with progression at 3 months. Functional parameters of DCE-US representing blood volume at baseline, day 8, and day 21 correlated with 3-month disease progression status.Interpretation This novel approach of sequential investigations in a phase I trial was feasible, detecting early changes in gene expression and tumour vascularity that may be predictive of clinical outcome.

2010-07-31 | E-TABM-760 | biostudies-arrayexpress

A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients.

Project description:Interventions: Patients receive aflibercept (4 mg/kg) every 2 weeks on day 1 of each cycle followed immediately by FOLFIRI. Treatment continues until disease progression, unacceptable toxicity, death, patient refusal, or investigator decision. Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose

| 2615831 | ecrin-mdr-crc

Isolation of two new Dehalococcoides mccartyi strains with dissimilar dechlorination functions and their characterization by comparative genomics via microarray analysis

Project description:Microbial reductive dechlorination of trichloroethene (TCE) in groundwater often results in the accumulation of dichloroethenes (DCEs). Dehalococcoides mccartyi (Dhc) are the only known bacteria capable of dechlorination beyond DCE to non-toxic ethene. In this study, two newly isolated Dhc strains (11a and 11a5) with dissimilar functional abilities are described. Strain 11a reductively dechlorinates TCE, 1,1-DCE, cis-DCE, trans-DCE, and vinyl chloride (VC) to ethene, while strain 11a5 dechlorinates TCE and all three DCE isomers only to VC. Each of these dechlorination reactions are coupled to growth by these strains. The VC dechlorination rate of strain 11a occurs at a rate of 258 nmol per min per mg of protein, about two times faster than previously reported stains. Strain 11a possesses the vcrA gene while strain 11a5 contains the tceA gene. Strains 11a and 11a5 share 100% 16S rRNA gene sequence identity with previously sequenced Dhc strains BAV1 and CBDB1, placing it within the Pinellas subgroup, and 85.4% and 89.5% of all genes present in the CBDB1 and BAV1 genomes were detected in strains 11a and 11a5, respectively, using a custom-designed microarray targeting four sequenced Dhc strains. Genes that were not detected in strains 11a and 11a5 are mostly within the high plasticity regions or integrated elements of the sequenced strains. This study reports the functional description and comparative genomics of two additional Dhc isolates and provides evidence that the observed functional incongruence between the activity and core genome phylogenies of Dhc strains is likely driven by the horizontal transfer of key reductive dehalogenase-encoding genes.

2013-03-01 | GSE27611 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data